Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420)
China
· Delayed Price · Currency is CNY 12.28
-0.19 (-1.52%)
Nov 15, 2024, 3:00 PM CST
Shanghai Shyndec Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 11,218 | 11,787 | 12,810 | 13,756 | 12,408 | 12,051 | Upgrade
|
| Other Revenue | 282.98 | 282.98 | 149.79 | 189.06 | 147.99 | 148.54 | Upgrade
|
| Revenue | 11,501 | 12,070 | 12,959 | 13,945 | 12,556 | 12,199 | Upgrade
|
| Revenue Growth (YoY) | -7.26% | -6.86% | -7.07% | 11.06% | 2.93% | 7.76% | Upgrade
|
| Cost of Revenue | 7,121 | 7,538 | 8,091 | 7,909 | 6,765 | 6,239 | Upgrade
|
| Gross Profit | 4,381 | 4,532 | 4,868 | 6,036 | 5,791 | 5,960 | Upgrade
|
| Selling, General & Admin | 2,207 | 2,906 | 3,414 | 4,220 | 4,049 | 4,268 | Upgrade
|
| Research & Development | 601.56 | 562.24 | 517.14 | 584.97 | 493.67 | 412.76 | Upgrade
|
| Other Operating Expenses | 58.84 | 115.06 | 113.17 | 128.31 | 127.33 | 134.16 | Upgrade
|
| Operating Expenses | 2,850 | 3,565 | 4,027 | 4,958 | 4,696 | 4,822 | Upgrade
|
| Operating Income | 1,531 | 967.35 | 841.24 | 1,078 | 1,095 | 1,138 | Upgrade
|
| Interest Expense | -37.66 | -57.88 | -107.31 | -110.47 | -123.51 | -189.44 | Upgrade
|
| Interest & Investment Income | 160.08 | 136.48 | 61.69 | 48.84 | 36.78 | 51.65 | Upgrade
|
| Currency Exchange Gain (Loss) | 28.44 | 28.44 | 98.32 | -32.65 | -64.01 | 21.74 | Upgrade
|
| Other Non Operating Income (Expenses) | -33.56 | -4.09 | -4.23 | -5.75 | -9.6 | -10.17 | Upgrade
|
| EBT Excluding Unusual Items | 1,648 | 1,070 | 889.71 | 978 | 934.57 | 1,012 | Upgrade
|
| Impairment of Goodwill | - | - | - | -132.15 | -44.76 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -24.04 | -21.81 | -42.81 | Upgrade
|
| Gain (Loss) on Sale of Assets | -36.14 | -31.85 | -1.1 | 0.2 | 23.92 | -14.57 | Upgrade
|
| Asset Writedown | -56.25 | -13.66 | -4.93 | -10.81 | -4.5 | -0.75 | Upgrade
|
| Other Unusual Items | 71.77 | 71.77 | 100.45 | 107 | 153.7 | 119.07 | Upgrade
|
| Pretax Income | 1,628 | 1,097 | 984.12 | 918.21 | 1,041 | 1,073 | Upgrade
|
| Income Tax Expense | 261.08 | 131.95 | 116.63 | 97.06 | 141.08 | 144.39 | Upgrade
|
| Earnings From Continuing Operations | 1,367 | 964.61 | 867.48 | 821.15 | 900.05 | 928.47 | Upgrade
|
| Minority Interest in Earnings | -284.07 | -272.73 | -239.69 | -252.87 | -251.25 | -272.1 | Upgrade
|
| Net Income | 1,082 | 691.88 | 627.79 | 568.28 | 648.79 | 656.37 | Upgrade
|
| Net Income to Common | 1,082 | 691.88 | 627.79 | 568.28 | 648.79 | 656.37 | Upgrade
|
| Net Income Growth | 41.44% | 10.21% | 10.47% | -12.41% | -1.15% | -6.97% | Upgrade
|
| Shares Outstanding (Basic) | 1,341 | 1,273 | 1,027 | 1,027 | 1,027 | 1,051 | Upgrade
|
| Shares Outstanding (Diluted) | 1,341 | 1,273 | 1,156 | 1,178 | 1,179 | 1,152 | Upgrade
|
| Shares Change (YoY) | 9.07% | 10.13% | -1.82% | -0.14% | 2.42% | 5.45% | Upgrade
|
| EPS (Basic) | 0.81 | 0.54 | 0.61 | 0.55 | 0.63 | 0.62 | Upgrade
|
| EPS (Diluted) | 0.81 | 0.54 | 0.54 | 0.48 | 0.55 | 0.57 | Upgrade
|
| EPS Growth | 29.67% | 0.07% | 12.52% | -12.29% | -3.49% | -11.78% | Upgrade
|
| Free Cash Flow | 2,036 | 1,363 | 2,548 | 1,158 | 1,182 | 866.32 | Upgrade
|
| Free Cash Flow Per Share | 1.52 | 1.07 | 2.20 | 0.98 | 1.00 | 0.75 | Upgrade
|
| Dividend Per Share | 0.200 | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | Upgrade
|
| Dividend Growth | 100.00% | 0% | 0% | 0% | 0% | 0% | Upgrade
|
| Gross Margin | 38.09% | 37.55% | 37.57% | 43.28% | 46.12% | 48.86% | Upgrade
|
| Operating Margin | 13.31% | 8.01% | 6.49% | 7.73% | 8.72% | 9.33% | Upgrade
|
| Profit Margin | 9.41% | 5.73% | 4.84% | 4.08% | 5.17% | 5.38% | Upgrade
|
| Free Cash Flow Margin | 17.70% | 11.29% | 19.66% | 8.31% | 9.42% | 7.10% | Upgrade
|
| EBITDA | 2,306 | 1,766 | 1,671 | 1,857 | 1,821 | 1,861 | Upgrade
|
| EBITDA Margin | 20.05% | 14.63% | 12.90% | 13.31% | 14.51% | 15.25% | Upgrade
|
| D&A For EBITDA | 774.89 | 798.51 | 830.01 | 778.52 | 726.41 | 722.4 | Upgrade
|
| EBIT | 1,531 | 967.35 | 841.24 | 1,078 | 1,095 | 1,138 | Upgrade
|
| EBIT Margin | 13.31% | 8.01% | 6.49% | 7.73% | 8.72% | 9.33% | Upgrade
|
| Effective Tax Rate | 16.04% | 12.03% | 11.85% | 10.57% | 13.55% | 13.46% | Upgrade
|
| Revenue as Reported | 11,501 | 12,070 | 12,959 | 13,945 | 12,556 | 12,199 | Upgrade
|
| Advertising Expenses | - | 4.64 | 3.29 | 7.1 | 6.43 | 7.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.